Furthermore, the closest reported breakpoints in ERG fusions to the ERG breakpoints identified in our case (chr21:40033588) are seen in rare variants of TMPRSS2-ERG (only 1.17% of the characterized and reported ERG fusions in prostate cancer (COSF123)). This evidence concerns the gene ERG and prostate carcinoma.